Current Advances in Vaccine Development for Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV)

Abstract

Severe fever with thrombocytopenia syndrome (SFTS), caused by the tick-borne severe fever with thrombocytopenia syndrome virus (SFTSV), is a disease that is endemic to East Asia and has mortality rates reaching 30%. Despite its substantial public health impact, no vaccines or antiviral treatments are currently available. The SFTSV genome encodes key structural proteins, including glycoproteins (Gn and Gc) and nucleocapsid protein (NP), which serve as critical vaccine targets. This Commentary reviews the current status of SFTSV-related vaccine platforms-such as viral vectors, inactivated viruses, DNA, mRNA, and protein-based approaches-and highlights the immune responses elicited by these platforms against key antigens, particularly glycoproteins and NP. Future research directions are additionally proposed to accelerate the development of effective SFTSV vaccines by leveraging insights from existing studies.

Keywords

Tick / Vector / Viral diseases / Zoonoses / Arbovirus / Pathogen

References

[1] Wang Y, Song Z, Wei X, Yuan H, Xu X, Liang H, et al. Clinical laboratory parameters and fatality of severe fever with thrombocytopenia syndrome patients: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2022; 16(6): e0010489.

[2] Qian J, Wei J, Ren L, Liu Y, Feng L. Sex differences in incidence and fatality of severe fever with thrombocytopenia syndrome: a comparative study based on national surveillance data of China. J Med Virol. 2023; 95(3): e28632.

[3] He Z, Wang B, Li Y, Du Y, Ma H, Li X, et al. Severe fever with thrombocytopenia syndrome: a systematic review and meta-analysis of epidemiology, clinical signs, routine laboratory diagnosis, risk factors, and outcomes. BMC Infect Dis. 2020; 20: 1-12.

[4] Yu XJ, Liang MF, Zhang SY, Liu Y, Li JD, Sun YL, et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med. 2011; 364(16): 1523-1532.

[5] Wang F, Wu Y, Jiao J, Wang J, Ge Z. Risk factors and clinical characteristics of severe fever with thrombocytopenia syndrome. Int J Gen Med. 2020; 13: 1661-1667.

[6] Li D. Severe fever with thrombocytopenia syndrome: a newly discovered emerging infectious disease. Clin Microbiol Infect. 2015; 21(7): 614-620.

[7] Miao D, Dai K, Zhao GP, Li XL, Shi WQ, Zhang JS, et al. Mapping the global potential transmission hotspots for severe fever with thrombocytopenia syndrome by machine learning methods. Emerg Microbes Infect. 2020; 9(1): 817-826.

[8] Kim E-H, Park S-J. Emerging tick-borne Dabie bandavirus: virology, epidemiology, and prevention . Microorganisms. 2023; 11(9): 2309.

[9] Raghavan RK, Barker SC, Cobos ME, Barker D, Teo EJM, Foley DH, et al. Potential spatial distribution of the newly introduced long-horned tick, Haemaphysalis longicornis in North America. Sci Rep. 2019; 9(1): 498.

[10] Plegge T, Hofmann-Winkler H, Spiegel M, Pöhlmann S. Evidence that processing of the severe fever with thrombocytopenia syndrome virus Gn/Gc polyprotein is critical for viral infectivity and requires an internal Gc signal peptide. PLoS One. 2016; 11(11): e0166013.

[11] Halldorsson S, Behrens AJ, Harlos K, Huiskonen JT, Elliott RM, Crispin M, et al. Structure of a phleboviral envelope glycoprotein reveals a consolidated model of membrane fusion. Proc Natl Acad Sci U S A. 2016; 113(26): 7154-7159.

[12] Kitagawa Y, Sakai M, Shimojima M, Saijo M, Itoh M, Gotoh B. Nonstructural protein of severe fever with thrombocytopenia syndrome phlebovirus targets STAT2 and not STAT1 to inhibit type I interferon-stimulated JAK-STAT signaling. Microbes Infect. 2018; 20(6): 360-368.

[13] Khalil J, Kato H, Fujita T. The role of non-structural protein NSs in the pathogenesis of severe fever with thrombocytopenia syndrome. Viruses. 2021; 13(5): 876.

[14] Hong Y, Bai M, Qi X, Li C, Liang M, Li D, et al. Suppression of the IFN-α and -β induction through sequestering IRF7 into viral inclusion bodies by nonstructural protein NSs in severe fever with thrombocytopenia syndrome bunyavirus infection. J Immunol. 2019; 202(3): 841-856.

[15] Zhou H, Sun Y, Wang Y, Liu M, Liu C, Wang W, et al. The nucleoprotein of severe fever with thrombocytopenia syndrome virus processes a stable hexameric ring to facilitate RNA encapsidation. Protein Cell. 2013; 4(6): 445-455.

[16] Li JC, Ding H, Wang G, Zhang S, Yang X, Wu YX, et al. Dynamics of neutralizing antibodies against severe fever with thrombocytopenia syndrome virus. Int J Infect Dis. 2023; 134: 95-98.

[17] Lv SM, Yuan C, Zhang L, Wang YN, Dai ZN, Yang T, et al. Severe fever with thrombocytopenia syndrome with re-infection in China: a case report. Infect Dis Poverty. 2021; 10(1): 90.

[18] Yu KM, Park SJ, Yu MA, Kim YI, Choi Y, Jung JU, et al. Cross-genotype protection of live-attenuated vaccine candidate for severe fever with thrombocytopenia syndrome virus in a ferret model. Proc Natl Acad Sci U S A. 2019; 116(52): 26900-26908.

[19] Yoshikawa T, Taniguchi S, Kato H, Iwata-Yoshikawa N, Tani H, Kurosu T, et al. A highly attenuated vaccinia virus strain LC16m8-based vaccine for severe fever with thrombocytopenia syndrome. PLoS Pathog. 2021; 17(2): e1008859.

[20] Dong F, Li D, Wen D, Li S, Zhao C, Qi Y, et al. Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus. NPJ Vaccines. 2019; 4(1): 5.

[21] Hicks P, Manzoni TB, Westover JB, Petch RJ, Roper B, Gowen BB, et al. Safety, Immunogenicity, and efficacy of a recombinant vesicular stomatitis virus vectored vaccine against severe fever with thrombocytopenia syndrome virus and heartland bandavirus. Vaccines (Basel). 2024; 12(12): 1403.

[22] Tian L, Yan L, Zheng W, Lei X, Fu Q, Xue X, et al. A rabies virus vectored severe fever with thrombocytopenia syndrome (SFTS) bivalent candidate vaccine confers protective immune responses in mice. Vet Microbiol. 2021; 257: 109076.

[23] Zhao Z, Zheng W, Yan L, Sun P, Xu T, Zhu Y, et al. Recombinant human adenovirus type 5 co-expressing RABV G and SFTSV Gn induces protective immunity against rabies virus and severe fever with thrombocytopenia syndrome virus in mice. Front Microbiol. 2020; 11: 1473.

[24] Qian H, Tian L, Liu W, Liu L, Li M, Zhao Z, et al. Adenovirus type 5-expressing Gn induces better protective immunity than Gc against SFTSV infection in mice. NPJ Vaccines. 2024; 9(1): 194.

[25] Kim JY, Jeon K, Hong JJ, Park SI, Cho H, Park HJ, et al. Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSV. Sci Rep. 2023; 13(1): 8189.

[26] Li A, Dai X, Chen L, Liu L, Li C, Liu Y, et al. Immunogenicity and protective efficacy of an inactivated SFTS vaccine candidate in mice. Biosaf Health. 2022; 4(01): 45-52.

[27] Jung D, Rejinold NS, Kwak JE, Park SH, Kim YC. Nano-patterning of a stainless steel microneedle surface to improve the dip-coating efficiency of a DNA vaccine and its immune response. Colloids Surf B Biointerfaces. 2017; 159: 54-61.

[28] Kwak JE, Kim YI, Park SJ, Yu MA, Kwon HI, Eo S, et al. Development of a SFTSV DNA vaccine that confers complete protection against lethal infection in ferrets. Nat Commun. 2019; 10(1): 3836.

[29] Kang JG, Jeon K, Choi H, Kim Y, Kim HI, Ro HJ, et al. Vaccination with single plasmid DNA encoding IL-12 and antigens of severe fever with thrombocytopenia syndrome virus elicits complete protection in IFNAR knockout mice. PLoS Negl Trop Dis. 2020; 14(3): e0007813.

[30] Kim D, Lai CJ, Cha I, Kang S, Yang WS, Choi Y, et al. SFTSV Gn-Head mRNA vaccine confers efficient protection against lethal viral challenge. J Med Virol. 2023; 95(11): e29203.

[31] Kim JY, Jeon K, Park SI, Bang YJ, Park HJ, Kwak HW, et al. mRNA vaccine encoding Gn provides protection against severe fever with thrombocytopenia syndrome virus in mice. NPJ Vaccines. 2023; 8(1): 167.

[32] Lu J, Liu J, Wu Y, He X, Gao X, Chen X, et al. A full-length glycoprotein mRNA vaccine confers complete protection against severe fever with thrombocytopenia syndrome virus, with broad-spectrum protective effects against bandaviruses. J Virol. 2024; 98(7): e0076924.

[33] Liu R, Huang DD, Bai JY, Zhuang L, Lu QB, Zhang XA, et al. Immunization with recombinant SFTSV/NSs protein does not promote virus clearance in SFTSV-infected C57BL/6J mice. Viral Immunol. 2015; 28(2): 113-122.

[34] Kim S, Jeon K, Choi H, Jeong DE, Kang JG, Cho NH. Comparative analysis of the efficacy of vaccines using structural protein subunits of the severe fever with thrombocytopenia syndrome virus. Front Microbiol. 2024; 15: 1348276.

[35] Kim D, Kim E, Kim S, Chung Y, Lai C-J, Cha I, et al. Self-assembling Gn head ferritin nanoparticle vaccine provides full protection from lethal challenge of Dabie bandavirus in aged ferrets . Mbio. 2023; 14(5): e0186823.

[36] Sette A, Sidney J, Crotty S. T cell responses to SARS-CoV-2. Annu Rev Immunol. 2023; 41(1): 343-373.

[37] Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016; 351(6279): 1339-1342.

[38] Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021; 21(2): 83-100.

[39] Ali MG, Zhang Z, Gao Q, Pan M, Rowan EG, Zhang J. Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview. Immunol Res. 2020; 68: 325-339.

[40] Han X, Xu P, Ye Q. Analysis of COVID-19 vaccines: types, thoughts, and application. J Clin Lab Anal. 2021; 35(9): e23937.

[41] Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004; 172(5): 2731-2738.

[42] Estes JD, Wong SW, Brenchley JM. Nonhuman primate models of human viral infections. Nat Rev Immunol. 2018; 18(6): 390-404.